Hims & Hers Health is upgraded to a speculative Buy after a 20% drop, with growth potential in GLP-1 sales outweighing key ...

HIMS accelerates global expansion with tech-integrated care, leveraging ZAVA and semaglutide for personalized health delivery.

Is Hims & Hers the next big player in telehealth? Our experts break down its business model, growth potential, and the risks ...

Progressive activists in Hassan demand timely opening of super speciality hospital for improved health services.

Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY ...

Popular digital weight loss app, Noom (NOOM) undercuts Novo Nordisk's Wegovy by offering quarter-dose packs at $119 for the ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive ...

Novo Nordisk A/S (NYSE: NVO) is one of the top oversold NYSE stocks to buy now. In a report released on August 4, Emily Field from Barclays maintained a Hold rating on Novo Nordisk A/S (NYSE:NVO), ...

Novo Nordisk’s head of U.S. marketing, Ulrich Otte, is no longer in the role and is exploring other internal opportunities at the company outside of the U.S.

Snowflake is positioned as a core enterprise platform for AI-driven data workloads. Its architecture supports deployment ...

Detailed price information for Becton Dickinson and Company (BDX-N) from The Globe and Mail including charting and trades.